|
Please
download and print the PDF file below:
|
|
|
|
Ajay K. Singh, MB, MRCP,
|
Ajay K. Singh, MB, MRCP, is Clinical Chief,
Renal Division Brigham and Women’s Hospital;
Associate Professor of Medicine, Harvard Medical
School, Boston, MA.
|
|
Paula Hertello
|
Paula Hertello is Project Manager, Renal Division
Brigham and Women’s Hospital, Boston, MA.
|
It is important for nephrology nurses to understand the relationship that exists between renal
disease, cardiac disease, and anemia. Even mild cases of chronic kidney disease (CKD) have
been associated with an increase in adverse cardiovascular outcomes. And anemia, which
can result from both CKD and congestive heart failure, has been shown to exacerbate the
adverse consequences of these conditions. An early, aggressive correction of anemia in
patients with CKD can be implemented to break this cycle and stop disease progression.
Studies have shown that anemia correction improves both cardiac and renal function and
can result in increased hemoglobin levels, decreased number of hospital days, and improved
quality of life. An effective strategy for managing anemia in patients with renal disease and
comorbid cardiovascular disease includes the administration of both recombinant human
erythropoietin and intravenous iron. In addition, the nephrology nurse plays an integral role
in managing anemia and improving outcomes in these patients. Therefore, the nephrology
nurse should have an increased awareness of the link between anemia and renal/cardiac disease
as well as available treatment options.
|
|
CE
RELATED INFORMATION |
|
This
offering for 1.8 contact
hours is being provided by
the
American
Nephrology Nurses Association
(ANNA), which
is accredited as a provider
and approver of continuing
education in nursing by
the American Nurses
Credentialing Center-Commission
on Accreditation (ANCCCOA).
This educational activity
is approved by most states
and specialty organizations
that recognize the ANCC-COA
accreditation process. ANNA
is an approved provider of
continuing education in nursing
by the California Board of
Registered Nursing, BRN Provider
No. 00910.
|
|
Goal:
To understand the association among anemia, renal disease, and cardiac disease and the
benefits of IV iron therapy in managing patients with anemia of renal/cardiac disease
Objectives:
1.
Discuss the relationship among anemia, renal disease, and cardiac disease.
2. Identify the benefits of IV iron therapy in managing the anemia of renal/
cardiac disease.
3. Describe the nephrology nurse’s role in treating this patient population.
|
AUTHOR DISCLOSURE
STATEMENT |
Ajay K. Singh, MB, MRCP, has
no conflicts of interest to disclose.
Paula Hertello has
no conflicts of interest to disclose.
|
ANNA and HDCN CE POLICY STATEMENTS |
The CE policy and disclosure statements of the American Nephrology
Nurses' Association are given in detail on the Symposium
Home Page. The CE policy statements of HDCN are listed on
this page. |